July 31, 2026Journal of the American College of Cardiology
Anemia and Chronic Heart Failure
Key result
EPO and IV iron for anemia in heart failure lack definitive safety and threshold data.
Why the study?
Does treating anemia with recombinant erythropoietin and intravenous iron improve outcomes in patients with chronic heart failure?
Population
Patients with chronic heart failure and anemia
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Anemia is a common comorbidity in heart failure associated with poor outcomes, and while early studies suggest benefit from treating it, large trials are needed to confirm safety and efficacy.
Key Points
- To review the mechanisms driving anemia in chronic heart failure and assess the therapeutic viability and safety of correcting red blood cell deficits.
- Synthesized mechanistic and clinical evidence examining renal impairment, neurohormonal pathways, cytokine activation, and defective iron utilization in heart failure.
- Evaluated findings from small-scale interventional trials of recombinant erythropoietin and intravenous iron, alongside designs of large ongoing trials (TREAT and RED-HF).
- Anemia arises multifactorially from chronic disease mechanisms, depressed bone marrow activity, and blunted erythropoietin responses, which in turn increase myocardial workload.
- Small trials show preliminary functional benefits with recombinant erythropoietin and intravenous iron, but optimal hemoglobin thresholds and cardiovascular safety remain undefined.
Structured PICO
Does treating anemia with recombinant erythropoietin and intravenous iron improve outcomes in patients with chronic heart failure?
P
Population
Patients with chronic heart failure and anemia
I
Intervention
Recombinant erythropoietin and intravenous iron
Anemia is a common comorbidity in heart failure associated with poor outcomes, and while early studies suggest benefit from treating it, large trials are needed to confirm safety and efficacy.
Limitations
- Safety concerns that recombinant erythropoietin therapy may be associated with adverse cardiovascular outcomes in chronic kidney disease and may worsen cancer.
Cite This Study
Inder S. Anand (2008) conducted a review in Chronic heart failure with anemia. Recombinant erythropoietin and intravenous iron was evaluated. Treating anemia in heart failure with recombinant erythropoietin and intravenous iron requires further prospective trials to determine ideal thresholds and safety.